NOT MEDICAL ADVICE. No information on this site should be considered medical advice. Research peptides are not intended for human consumption — in-vitro lab use only. Consult a physician prior to introducing anything into the human body.
Peptide HubResearch Peptide Wiki
Support Us Join

Home/Weight Loss & Metabolic/Amylin Analogs (Expanded)

Amylin Analogs (Expanded)

Class listing for synthetic analogs of the pancreatic hormone amylin; pramlintide is the approved reference agent, while novel long-acting analogs are investigational.

Overview

This listing groups synthetic analogs of amylin, the 37-amino-acid pancreatic hormone co-secreted with insulin. The best-documented amylin analog is pramlintide, an approved drug used as an adjunct to mealtime insulin in diabetes; newer long-acting analogs, such as cagrilintide, are in clinical development for weight management. The exact peptides sold by individual vendors under this category heading are not always disclosed.

Mechanism

Amylin and its analogs signal through amylin receptors, complexes of the calcitonin receptor with receptor-activity-modifying proteins, in regions that include the hindbrain area postrema. Receptor activation slows gastric emptying, suppresses glucagon secretion, and reduces food intake, effects that underlie the clinical use of pramlintide.

Dosing

Pramlintide, the only approved amylin analog, is given by subcutaneous injection before meals according to a fixed clinical titration. Investigational long-acting analogs are studied as once-weekly subcutaneous injections. For uncharacterized analog products in this category, no dosing information can responsibly be provided.

  • Pramlintide (approved): subcutaneous injection before meals, titrated in clinical practice
  • Long-acting analogs in development: subcutaneous, designed for weekly administration
  • Unspecified catalog analog products have no established dosing

Expected Effects

  • Reduced postprandial glucose excursions via delayed gastric emptying and glucagon suppression
  • Increased satiety and reduced food intake, the basis of weight-management trials
  • Effect magnitude depends on the specific analog and dose

Side Effects & Tolerability

For the approved agent pramlintide, nausea is the most common tolerability concern, and hypoglycemia risk increases when it is combined with insulin. Novel long-acting analogs show similar class-typical gastrointestinal effects in trials. Nothing can responsibly be said about unspecified catalog products.

Storage

Approved and investigational amylin analogs are handled as pharmaceutical peptides; storage (typically refrigerated) follows the product label. For generic amylin-analog research products, follow the supplier's storage instructions.

Related peptides

AdipotideInvestigational prohibitin-targeting pro-apoptotic peptide conjugate studied in obese mice and monkeys to reduce adipose vasculature; not tested in humans.Advanced Thermogenic Master AnalogsMarketing-style catalog label implying peptides that enhance thermogenesis; no defined compound exists under this name in the literature.AMPK & mTOR Balance AnalogsCatalog label implying peptides that modulate the AMPK/mTOR signaling balance; no specific compounds are characterized under this name.Autophagy Enhancer Peptide AnalogsCatalog category for peptides claimed to enhance autophagy; not a recognized compound class in the literature.C-Peptide AnalogsSynthetic peptides related to the proinsulin connecting peptide, whose native form has been studied as an adjunct in type 1 diabetes; analogs are undocumented.CagrilintideLong-acting synthetic amylin analog in clinical development for obesity, often studied with semaglutide as the combination referred to as CagriSema.